Immunotherapy has emerged as a new treatment modality in breast cancer, with immune checkpoint blockade (ICB) to target and block PD-1, PD-L1, and CTLA-4 approved as first-line therapy in metastatic triple-negative breast cancer [48–50]. The gene discussed is CTLA4; the disease is triple-negative breast carcinoma.